Aceclofenac-loaded chondroitin sulfate conjugated SLNs for effective management of osteoarthritis. (November 2014)

• Record Type: Journal Article
• Authors: Bishnoi, Mamta; Jain, Ankit; Hurkat, Pooja; Jain, Sanjay K.
• Is Part Of: Journal of drug targeting. Volume 22:Number 9(2014)
• Page Start: 805
• Page End: 812
• Publication Date: 2014-11
• Subjects: Drug delivery systems -- Periodicals; Drug Delivery Systems; Vehicles; Drug Administration Routes; Drug Evaluation; 615.7
• DOI: 10.3109/1061186X.2014.928714
• Languages: English
• ISSNs: 1061-186X

Abstract

<abstract> <title>Abstract</title> <p> <italic>Background</italic>: In intra-articular drug delivery, there are number of shortcomings such as lymphatic drainage from the synovial cavity, frequent dosing, adverse side effects and patient discomfort in the management of osteoarthritis (OA).</p> <p> <italic>Purpose</italic>: This research work reports the development and characterization of aceclofenac-loaded chondroitin sulfate (CS) conjugated (CS-SLN) and unconjugated solid lipid nanoparticles (SLN) for the effective management of OA.</p> <p> <italic>Methods</italic>: The SLNs were prepared using modified solvent injection method and coupled with CS. They were further characterized for size and size distribution, zeta potential, surface morphology, % entrapment efficiency and <italic>in vitro</italic> drug release profile. Anti-inflammatory activity and <italic>in vivo</italic> performance was also predicted.</p> <p> <italic>Results</italic>: The particle size of the SLN and CS-SLN was found to be 143.4 ± 0.9 nm and 154.2 ± 1.1 nm, respectively. SLNs exhibited sustained drug release (SLN, 64.25 ± 0.75%; CS-SLN, 57.82 ± 0.62%) <italic>in vitro</italic> for more than 24 h. <italic>In vivo</italic> performance studies revealed the highest uptake of SLNs by the knee joint.</p> <p> <italic>Discussion</italic>: SLNs enhanced accumulation at the knee joint due to specific interactions with CD44, annexin and leptin receptors attributed to CS coupling.</p> <p> <italic>Conclusion</italic>: CS-SLN could be potentially effective vector for the treatment or management of OA.</p> </abstract>